Travere Therapeutics (TVTX) Assets (2011 - 2026)

Travere Therapeutics' Assets history runs 16 years deep, the most recent figure standing at $555.2 million for Q1 2026.

• Quarterly Assets rose 1.16% year-over-year to $555.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $555.2 million (up 1.16% YoY) and the FY2025 annual result came in at $605.2 million, up 1.86% from the prior year.
• Assets was $555.2 million for Q1 2026 at Travere Therapeutics, down from $605.2 million in the prior quarter.
• Across five years, Assets topped out at $832.8 million in Q3 2023 and bottomed at $504.4 million in Q3 2024.
• A 5-year average of $664.1 million and a median of $663.5 million in 2024 frame the typical range for Assets.
• Annual changes were most pronounced in 2023 — Assets increased 17.3% — and 2024, when it plunged 39.44%.
• Travere Therapeutics' Assets stood at $672.6 million in 2022, then rose by 17.3% to $788.9 million in 2023, then decreased by 24.69% to $594.1 million in 2024, then gained by 1.86% to $605.2 million in 2025, then fell by 8.26% to $555.2 million in 2026.
• Business Quant data shows TVTX's Assets at $555.2 million in Q1 2026, $605.2 million in Q4 2025, and $538.6 million in Q3 2025.